|
|
|
| Study of the characteristics of benefit population-based on patients with taking the first generation of EGFR-TKIs and drug resistance prolonged by traditional Chinese medicine |
| GAO Ruike* WU Zhe* LI Jie ZHANG Xiaoxiao ZHU Guanghui |
| Department of Oncology, Guang′anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China |
|
|
|
Abstract Objective To explore the characteristics of the benefit population-based on patients with taking the first generation of EGFR-TKIs and drug resistance prolonged by traditional Chinese medicine. Methods A retrospective collection of patients with non-small cell lung cancer taking EGFR-TKIs who were hospitalized in Guang′anmen Hospital of Chinese Academy of Chinese Medical Sciences from January 2006 to December 2017 and continued to receive traditional Chinese medicine in the outpatient clinic of this hospital after discharge. Progression-free survival (PFS) time was used as the main efficacy index. Results This study included 90 patients with a median PFS time of 9.6 months. Kaplan-Meier univariate survival analysis showed that PFS time was prolonged in 90 patients with the female, no smoking history, no drinking history, peripheral lung cancer, adenocarcinoma, no adrenal metastasis, no liver metastasis, no atelectasis, adverse reactions after taking EGFR-TKIs, syndrome of qi deficiency of lung and spleen and phlegm and blood stasis. Multivariate Cox regression analysis, found that adverse reactions occurred after taking EGFR-TKIs, peripheral lung cancer, no adrenal metastasis were independent protective factors (P ＜ 0.05). Compared with other types of syndromes, syndrome of qi deficiency of lung and spleen and phlegm and blood stasis may be protective factors. Conclusion The characteristics of the benefit population-based on taking the first generation of EGFR-TKIs and drug resistance prolonged by traditional Chinese medicine may be peripheral lung cancer, no adrenal metastasis, syndrome of qi deficiency of lung and spleen and phlegm and blood stasis.
|
|
|
|
|
|
[1] Yu HA，Riely GJ，Lovly CM. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors [J]. Clin Cancer Res，2014，20（23）：5898-5907.
[2] Jia Y，Yun CH，Park E，et al. Overcoming EGFR（T790M）and EGFR（C797S）resistance with mutant-selective allosteric inhibitors [J]. Nature，2016，534（7605）：129-132.
[3] Janne PA，Yang JC，Kim DW，et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer [J]. N Engl J Med，2015，372（18）：1689-1699.
[4] 翁霆耀，凌雅萍.中医药联合分子靶向药物治疗非小细胞肺癌的系统评价[J].临床医药文献电子杂志，2018，5（45）：171-173.
[5] 支修益，石远凯，于金明.中国原发性肺癌诊疗规范（2015年版）[J].中华肿瘤杂志，2015，37（1）：67-78.
[6] Edge SB，Byrd DR，Compton CC，et al. AJCC Cancer Staging Manual，7th ed [M]. New York：Springer，2010：253-270.
[7] Travis WD，Brambilla E，Burke AP，et al. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung，Pleura，Thymus，and Heart [J]. J Thorac Oncol，2015，10（9）：1240-1242.
[8] 林洪生.恶性肿瘤中医诊疗指南[M].北京：人民卫生出版社，2014：254-257.
[9] Maemondo M，Inoue A，Kobayashi K，et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR [J]. N Engl J Med，2010，362（25）：2380-2388.
[10] Rosell R，Carcereny E，Gervais R，et al. Erlotinib versus standard chemotherapy as first-line treatment for Europeanpatients with advanced EGFR mutation-positive non-small-cell lung cancer（EURTAC）：A multicentre，open-label，randomised phase 3 trial [J]. Lancet Oncol，2012，13（3）：239-246.
[11] Shi Y，Zhang L，Liu X，et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer（ICOGEN）：a randomised，doubleblind phase 3 non-inferiority trial [J]. Lancet Oncol，2013，14（10）：953-961.
[12] Griffin R，Ramirez RA. Molecular Targets in Non-Small Cell Lung Cancer [J]. Ochsner J，2017，17（4）：388-392.
[13] 许海柱，张璇，孙建立.EGFR-TKIs结合中医药治疗晚期非小细胞肺癌的多因素分析[J].时珍国医国药，2017， 28（9）：2156-2158.
[14] Jiao L，Xu J，Sun J，et al. Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma（CATLA）：A Multicenter，Randomized，Double-Blind，Placebo-Controlled Trial [J]. Front Pharmacol，2019，10：732.
[15] Soria JC，Mok TS，Cappuzzo F，et al. EGFR-mutated oncogene-addicted non-small cell lung cancer：current trends and future prospects [J]. Cancer Treat Rev，2012， 38（5）：416-430.
[16] Fukihara J，Watanabe N，Taniguchi H，et al. Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer [J]. Oncology，2014，6（2）：86-93.
[17] Lin JH，Lin D，Xu L，et al. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI）efficacy in advanced non-small-cell lung cancer patients：a retrospective assessment of 94 cases with EGFR mutations [J]. Oncotarget，2017，8（2）：3412-3421.
[18] 陈闽江，徐燕，赵静，等.表皮生长因子酪氨酸激酶抑制剂一线治疗突变阳性晚期非小细胞肺癌的临床疗效预测因素分析[J].中国肺癌杂志，2019，22（2）：99-104.
[19] Soulieres D，Senzer NN，Vokes EE，et al. Multicenter phase Ⅱ study of erlotinib， an oral epidermal growth factor receptor tyrosine kinase inhibitor，in patients with recurrent or metastatic squamous cell cancer of the head and neck [J]. J Clin Oncol，2004，22（1）：77-85.
[20] 李鹏.表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测及监测因素研究[D].济南：山东大学，2012.
[21] Tamura T，Kurishima K，Nakazawa K，et al. Specific organ metastases and survival in metastatic non small cell lung cancer [J]. Mol Clin Oncol，2015，3（1）：217-221.
[22] Hendriks LE，Derks JL，Postmus PE，et al. Single organ metastatic disease and local disease status，prognostic factors for overall survival in stage Ⅳ non-small cell lung cancer：results from a population-based study [J]. Eur J Cancer，2015，51（17）：2534-2544.
[23] 陈程，李凯.73例肺类癌的临床特征及预后分析[J].中国肺癌杂志，2009，12（6）：582-586.
[24] 封佳莉，李和根，周晓辉，等.中医药干预874例晚期非小细胞肺癌的生存分析[J].安徽中医药大学学报，2019， 38（6）：10-15.
[25] 谈婷婷.晚期非小细胞肺癌患者中医辨证分型与EGFR-TKIs治疗后无进展生存期相关性研究[D].武汉：湖北中医药大学，2019. |
|
|
|
